Home
Sitagliptin phosphate monohydrate

Sitagliptin phosphate monohydrate

In stock

Catalog No.

A4036

Potent DPP-4 inhibitor

Skip to the beginning of the images gallery

Grouped product items
Size	Price	Stock
10mM (in 1mL DMSO)	$55.00	In stock
Evaluation Sample	$28.00	In stock
200mg	$60.00	In stock
500mg	$110.00	In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background
Product Citation
Chemical Properties
Protocol
Biological Activity
Quality Control

Background

Sitagliptin phosphate monohydrate is the phosphate salt of its active component, sitagliptin, with one molecule of water. Sitagliptin is a potent inhibitor of dipeptidyl peptidase 4 (DPP-4), an enzyme catalyzing the cleavage of peptides with an N-terminal alanine or proline amino acid residue, that selectively inhibits DPP-4 with 50% inhibition concentration IC₅₀ value of 18 nM and shows no affinity towards other DDP enzymes (such as DDP-8 and DDP-9). The inhibition of DPP4 by sitagliptin has been found to be mediated by increasing levels of two DPP-4 substrates, including glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). Sitagliptin is currently being investigated in the treatment of type II diabetes.

Reference

Gallwitz B. Review of sitagliptin phosphate: a novel treatment for type 2 diabetes. Vasc Health Risk Manag. 2007;3(2):203-10.

Product Citation

1. Mansur SA, Mieczkowska A, et al. "Sitagliptin Alters Bone Composition in High-Fat-Fed Mice." Calcif Tissue Int. 2018 Dec 18. PMID:30564859
2. Ghorpade DS, Ozcan L, et al. "Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance." Nature. 2018 Mar 29;555(7698):673-677. PMID:29562231
3.Mroz PA, Perez-Tilve D, et al. "Native Design of Soluble, Aggregation-Resistant Bioactive Peptides: Chemical Evolution of Human Glucagon." ACS Chem Biol. 2016 Dec 16;11(12):3412-3420. PMID:27797473
4.Khan D, Vasu S, et al. "Islet distribution of Peptide YY and its regulatory role in primary mouse islets and immortalised rodent and human beta-cell function and survival." Mol Cell Endocrinol. 2016 Jul 25;436:102-113. PMID:27465830
5.Gault, V. A., R. Lennox, and P. R. Flatt. "Sitagliptin, a DPP‐4 inhibitor, improves recognition memory, oxidative stress, hippocampal neurogenesis and up‐regulates key genes involved in cognitive decline." Diabetes, Obesity and Metabolism (2015). PMID:25580570

Chemical Properties

Physical Appearance	A solid
Storage	Store at -20°C
M.Wt	523.3
Cas No.	654671-77-9
Formula	C₁₆H₁₅F₆N₅O.H₃PO₄.H₂O
Synonyms	Tesavel, MK-0431,MK0431
Solubility	≥23.8 mg/mL in DMSO, <2.41 mg/mL in EtOH, ≥30.6 mg/mL in H2O with ultrasonic
Chemical Name	(3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one;phosphoric acid;hydrate
SDF	Download SDF
Canonical SMILES	[HH].C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)CC(CC3=CC(=C(C=C3F)F)F)N.O.OOP(=O)=O
Shipping Condition	Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Protocol

Cell experiment [1]:
Cell lines	Endothelial progenitor cells (EPCs) and bone marrow mesenchymalstem cells(MSC)
Preparation method	The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.
Reaction Conditions	14 d; 25 μmol/L
Applications	To determine whether sitagliptin treatment participated in enhancing the differentiation of EPCs and MSCs and cells expressing its ligand, SDF-1α, adipose tissues were co-cultured with sitagliptin (25 μmol/L) in M199 culture medium for 14 d and examined by flow cytometric analysis. The results show that compared with the 7 d cell culture, the numbers of EPCs [CD31/Sca-1+(double-stained) and CXCR4+ (single-stained)] were remarkably higher at day 14 in both the non-sitagliptin-treated (Si-T) group and the Si-T group
Animal experiment [2]:
Animal models	ApoE−/−mice with the C57BL/6 genetic background
Dosage form	200 mg/kg/day; oral taken
Applications	In ApoE−/−mice, the sitagliptin group showed fewer atherosclerotic plaques than in controls (7.64±1.98% [range 4.62–10.13%] vs 12.91±1.15% [range 11.55–14.37%], p<0.001). Compared with control mice, atherosclerotic plaque areas decreased respectively 1.92- and 2.74-fold in the aortic root and abdominal aorta of mice fed sitagliptin (p=0.011 and p=0.006). Our data show that sitagliptin can inhibit the formation of atherosclerotic areas in entire aorta, aortic root and abdominal aorta of ApoE−/− mice.
Other notes	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
References: [1] Chua S, Sheu J J, Chen Y L, et al. Sitagliptin therapy enhances the number of circulating angiogenic cells and angiogenesis—evaluations< i> in vitro and in the rat critical limb ischemia model[J]. Cytotherapy, 2013, 15(9): 1148-1163. [2] Zeng Y, Li C, Guan M, et al. The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK-and MAPK-dependent mechanisms[J]. Cardiovascular diabetology, 2014, 13(1): 32.